clinical trial · NCT07446439
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
Nausea and VomitingObesityTradipitantPlacebo
brief summary
The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.
started
Mar 27, 2026
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Apr 20, 2026
official title
The Thetis Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tradipitant on Nausea and Vomiting After GLP-1R Agonist Administration in Healthy Overweight or Obese Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol